BioMarin Pharmaceutical Inc.

AI Score

0

Unlock

62.02
-0.51 (-0.82%)
At close: Jan 22, 2025, 3:59 PM
61.70
-0.52%
After-hours Jan 22, 2025, 04:47 PM EST

Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.

Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria.

The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.

BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd.

The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. logo
Country United States
IPO Date Jul 26, 1999
Industry Biotechnology
Sector Healthcare
Employees 3,401
CEO Alexander Hardy

Contact Details

Address:
770 Lindaro Street
San Rafael, California
United States
Website https://www.biomarin.com

Stock Details

Ticker Symbol BMRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001048477
CUSIP Number 09061G101
ISIN Number US09061G1013
Employer ID 68-0397820
SIC Code 2834

Key Executives

Name Position
Alexander Hardy President, Chief Executive Officer & Director
Amy Wireman Executive Vice President & Chief People Officer
Brian R. Mueller CPA Chief Financial Officer & Executive Vice President
Dr. C. Greg Guyer Ph.D. Executive Vice President & Chief Technology Officer
George Eric Davis J.D. Executive Vice President, Chief Legal Officer, General Counsel & Secretary
Humaira Serajuddin Senior Vice President & Chief Marketing Officer
Dr. Henry J. Fuchs M.D., Ph.D. Advisor
Dr. Kevin Eggan Ph.D. Chief Scientific Officer & Senior Vice President of Research and Early Development
Erin Burkhart Group Vice President & Chief Accounting Officer
Traci McCarty Group Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Dec 03, 2024 4 Filing
Nov 14, 2024 4 Filing
Oct 31, 2024 10-Q Quarterly Report
Oct 29, 2024 8-K Current Report
Oct 01, 2024 4 Filing
Oct 01, 2024 3 Filing
Sep 30, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Sep 24, 2024 8-K Current Report
Sep 17, 2024 4 Filing
Sep 04, 2024 8-K Current Report